-

Doctor Evidence (“DRE”) Named Member of The Trinity Challenge

AI-driven healthcare technology leader selected to participate in global initiative to better protect the world against health emergencies

SANTA MONICA, Calif.--(BUSINESS WIRE)--DRE announced today that it has been selected as a Member of The Trinity Challenge.

The Trinity Challenge was launched in September 2020 by Dame Sally Davies, the Master of Trinity College, Cambridge, and former Chief Medical Officer of England, who believes the use of data and analytics in global public health can mitigate risks and response time in the battle against health emergencies such as COVID-19. The Trinity Challenge calls on people from around the world to submit their ideas to safeguard our health and economic systems from the threat of future global health emergencies.

Dame Sally Davies commented, “Data lies at the heart of The Trinity Challenge. As we battle this second wave of the virus, we must leverage insights which make use of data and advanced analytics to find unique solutions that help us better prepare for future health emergencies.

“I am delighted to welcome Doctor Evidence as a Member to The Trinity Challenge and am confident that Challenge teams will benefit significantly from access to their suite of solutions. I invite all researchers and analysts to work with Doctor Evidence to enhance their ideas with unparalleled insights from their analytics and proprietary data platforms.”

Challenge participants will provide ideas and concepts addressing at least one of three areas in which to improve the approach towards pandemic prevention and control, framed as: 1) better identification, 2) better response; and, 3) better recovery.

“The Trinity Challenge offers an incredible opportunity for Members and challenge teams to bring accelerated solutions, like broad-scale, industry-wide drug discovery and repurposing candidates forward to address COVID-19,” said DRE’s CEO Bob Battista.

Joseph A. Boystak, DRE’s Chairman of the Board, commented, “We are honored to become a Member of The Trinity Challenge along with such an exceptional group of Founding Members and Members under the leadership of Dame Sally Davies. This group of Members intends to form unique collaborations and partnerships to harness extraordinary skills, technologies and domain knowledge in data and data analytics to rapidly identify new methodologies and solutions to immediately combat COVID-19 and other global health threats and emergencies. DRE intends to fully collaborate with Trinity Challenge Members to innovate solutions to the pandemic through the use of its platform.”

DRE will join Founding Members and Members that span the public, private and academic sectors and include organizations such as Bill and Melinda Gates Foundation, the IHME, Google, Microsoft, McKinsey & Company, Optum, GSK, Palantir, the University of Cambridge, among others in this urgent pursuit of future preparedness. DRE will provide Challenge participants with its software platforms to help them generate further insights and scale solutions.

About The Trinity Challenge:
Preparedness for health emergencies requires more than just pharmaceutical interventions. It demands that we better identify, respond to, and recover from outbreaks before they cause great harm. COVID-19 has starkly shown the need for better preparation.

The Trinity Challenge is an initiative led by some of the world’s most prominent organisations from across the private, academic, and social sectors for the purpose of sourcing and scaling solutions that better protect one billion more people from future health emergencies. It is a call to action for the world’s best and brightest minds to contribute ideas and innovations, with £10M in awards for the best Challenge Teams. Questions cover economics, behavioural sciences, epidemiology, and many other disciplines. Founding Members and Members will contribute their data, resources, and time to catalyse and support the work of Challenge Teams.

https://thetrinitychallenge.org/

About DRE:
DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable insights. DRE provides instant, continuous search and data analysis across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their clinical programs. Its technology platform provides DRE's customers with a Software-as-a-Service ("SaaS") Insights Engine which empowers them to make better decisions from lab to patient.

https://drevidence.com/

Contacts

Cathy Finley
+1 (310) 595-1265
pr@doctorevidence.com
https://drevidence.com/

Doctor Evidence


Release Versions

Contacts

Cathy Finley
+1 (310) 595-1265
pr@doctorevidence.com
https://drevidence.com/

More News From Doctor Evidence

Dr.Evidence Unveils Major Enhancements to AI-enabled Landscape Intelligence Platform for Life Sciences

SANTA MONICA, Calif.--(BUSINESS WIRE)--Dr.Evidence, the preeminent AI-enabled landscape intelligence platform helping life sciences enterprises get their products to market and keep them there, today announced significant enhancements to further accelerate clients’ time-to-market for new drugs and indications and de-risk the possibility of missing critical precedent from the market to support a successful path to approval. The Dr.Evidence platform incorporates the broadest global content set av...

Dr.Evidence® Launches Breakthrough Regulatory Intelligence Solution

SANTA MONICA, Calif.--(BUSINESS WIRE)--Dr.Evidence, the preeminent evidence-based insights platform for life sciences companies, today announced the launch of a groundbreaking new regulatory intelligence solution. Building on the company’s industry gold standard label intelligence solution, DocLabel, as well as its next generation scientific literature search engine, this new offering marks a significant advancement in regulatory support for the life sciences industry. The Dr.Evidence team will...

Dr.Evidence® Appoints Ken Kobayashi, MD, FACP to its Medical Strategy Advisory Board

SANTA MONICA, Calif.--(BUSINESS WIRE)--Dr.Evidence is pleased to announce the appointment of Ken Kobayashi, MD, FACP to the MSAB. He joins Chair, Calum MacRae, MB, ChB, PhD, BSc, and members, Michael Klag, MD, MPH, Frank Rockhold, PhD, ScM, BA, and David Tovey, MD. Dr. Kobayashi has a deep background as a clinician-scientist, regulator, scientific diplomat and drug developer across the US, Europe, Latin America, and Japan/Asia. As a senior executive in top-tier pharmaceutical companies includin...
Back to Newsroom